Cover Image
市場調查報告書

社區型細菌性肺炎:全球臨床實驗檢討

Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H1, 2017

出版商 GlobalData 商品編碼 320828
出版日期 內容資訊 英文 96 Pages
訂單完成後即時交付
價格
Back to Top
社區型細菌性肺炎:全球臨床實驗檢討 Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H1, 2017
出版日期: 2017年06月30日 內容資訊: 英文 96 Pages
簡介

社區型細菌性肺炎,會作為胸部疼痛,咳嗽,有痰,呼吸困難,寒氣,發冷,發熱,或和低血壓症相關,定義為肺實質的急性細菌感染,胸部X光掃描影像中,伴隨新的肺葉或多葉性浸潤的存在。引起內細菌性肺炎,代表性細菌性病原體,有肺炎球菌、流感菌、Moraxella catarrhalis等。還有肺炎披衣菌、肺炎黴漿菌、嗜肺性退伍軍人桿菌等,典型性的細菌性病原體,也引起社區型細菌性肺炎。

本報告提供社區型細菌性肺炎的治療藥相關臨床實驗調查分析、臨床實驗數及受驗人數、各階段及各方面狀況、有潛力的企業、正在開發的治療藥的資訊、臨床實驗簡介等相關的系統性資訊。

目錄

簡介

各地區的臨床實驗

  • 各國臨床實驗趨勢
    • 亞太地區的主要國家
    • 歐洲的主要國家
    • 北美的主要國家
    • 中東、非洲的主要國家
    • 中南美的主要國家

G7各國的臨床實驗:對感染性疾病臨床實驗的社區型細菌性肺炎的比例

G7各國的臨床實驗:各Phase

G7各國的臨床實驗:各階段

E7各國的臨床實驗:對感染性疾病臨床實驗的社區型細菌性肺炎的比例

E7各國的臨床實驗:各Phase

E7各國的臨床實驗:各階段

各方面的臨床實驗

各階段臨床實驗

各評估項目臨床實驗

未完成的臨床實驗

一定期間採用的實驗對象

贊助商各類型臨床實驗

有潛力的贊助商

  • 社區型細菌性肺炎的治療藥參與臨床實驗的主要企業

有前途藥物

臨床實驗簡介

  • 主要企業臨床實驗概要
    • Actavis plc
    • Cempra, Inc.
    • Pfizer Inc.
    • Cempra Pharmaceuticals, Inc.
    • AstraZeneca PLC
    • Nabriva Therapeutics AG
    • Cubist Pharmaceuticals, Inc.
    • Boehringer Ingelheim Auslandsbeteiligungs GmbH
    • Bayer AG
    • Basilea Pharmaceutica AG
  • 主要大學、研究機關、醫院臨床實驗概要
    • 橫濱勞災病院
    • Nagasaki Evaluation Organization for Clinical Interventions(NEOCI)
    • 中日本呼吸系統臨床研究機構(CJLSG)
    • Albany Medical Center

主要的臨床簡介

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4323CTIDB

GlobalData's clinical trial report, "Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H1, 2017" provides an overview of Community-Acquired Bacterial Pneumonia clinical trials scenario. This report provides top line data relating to the clinical trials on Community-Acquired Bacterial Pneumonia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • GlobalData Clinical Trials Report Coverage 7
  • Clinical Trials by Region 8
  • Clinical Trials and Average Enrollment by Country 9
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
  • Top Five Countries Contributing to Clinical Trials in Europe 13
  • Top Countries Contributing to Clinical Trials in North America 14
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 15
  • Top Five Countries Contributing to Clinical Trials in Central and South America 16
  • Clinical Trials by G7 Countries: Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials 17
  • Clinical Trials by Phase in G7 Countries 19
  • Clinical Trials in G7 Countries by Trial Status 20
  • Clinical Trials by E7 Countries: Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials 21
  • Clinical Trials by Phase in E7 Countries 23
  • Clinical Trials in E7 Countries by Trial Status 24
  • Clinical Trials by Phase 25
  • In Progress Trials by Phase 26
  • Clinical Trials by Trial Status 27
  • Clinical Trials by End Point Status 29
  • Subjects Recruited Over a Period of Time 30
  • Clinical Trials by Sponsor Type 31
  • Prominent Sponsors 32
  • Top Companies Participating in Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials 34
  • Prominent Drugs 36
  • Latest Clinical Trials News on Community-Acquired Bacterial Pneumonia 38
  • Jun 05, 2017: Nabriva Therapeutics Announces Webcast of Analyst & Investor Day on June 19, 2017 38
  • Jun 02, 2017: Nabriva Therapeutics to present data at ASM Microbe supporting ongoing Phase 3 clinical development program for lefamulin 38
  • Jun 02, 2017: Eight Presentations at ASM Microbe Include Late Breaker From Cempra's Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media 38
  • Apr 25, 2017: Omadacycline Concentrations Exceed Tigecycline Levels in Lungs and Epithelial Lining Fluid According to Pharmacokinetic/Pharmacodynamic Data 39
  • Apr 21, 2017: Cempra Presents Data at ECCMID Highlighting Need for New CABP Therapies and Activity of Solithromycin in Key Population Groups 40
  • Apr 13, 2017: Nabriva Therapeutics to present data at ECCMID supporting ongoing Phase 3 clinical development program for lefamulin 40
  • Apr 11, 2017: Nabriva Therapeutics Announces Enrollment Completion for LEAP 1, a Phase 3 Clinical Trial Evaluating Lefamulin in Community-Acquired Bacterial Pneumonia 41
  • Clinical Trial Profile Snapshots 42

Appendix 94

  • Abbreviations 94
  • Definitions 94
  • Research Methodology 95
  • Secondary Research 95
  • About GlobalData 96
  • Contact Us 96
  • Source 96

List of Tables

List of Tables

  • Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Region, 2017* 8
  • Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10
  • Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, North America, Top Countries, 2017* 14
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 15
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 16
  • Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 18
  • Community-Acquired Bacterial Pneumonia Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
  • Community-Acquired Bacterial Pneumonia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 22
  • Community-Acquired Bacterial Pneumonia Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 23
  • Community-Acquired Bacterial Pneumonia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 24
  • Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Phase, 2017* 25
  • Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 26
  • Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Trial Status, 2017* 28
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, by End Point Status, 2017* 29
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 30
  • Community-Acquired Bacterial Pneumonia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 31
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 33
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 35
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 37

List of Figures

List of Figures

  • Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
  • Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 15
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 16
  • Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 17
  • Community-Acquired Bacterial Pneumonia Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
  • Community-Acquired Bacterial Pneumonia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 21
  • Community-Acquired Bacterial Pneumonia Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 23
  • Community-Acquired Bacterial Pneumonia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 24
  • Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Phase (%), 2017* 25
  • Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 26
  • Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Trial Status, 2017* 27
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, by End Point Status, 2017* 29
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 30
  • Community-Acquired Bacterial Pneumonia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 31
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 32
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 34
  • Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 36
  • GlobalData Methodology 95
Back to Top